FDA Approved: EXEMESTANE — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Exemestane from Mylan Pharmaceuticals Inc., enabling a generic aromatase inhibitor to be marketed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)

Snippet

SUPPL AP for EXEMESTANE (EXEMESTANE)